Video Experimental Relacionado

Updated: Jan 7, 2026

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

Costo-efectividad del sotorasib frente al adagrasib en NSCLC avanzado con mutación G12C previamente tratado: una

Nadia Karim¹, David Waterhouse², Simon Jones³

¹Amgen Ltd, Health Economics and Outcomes Research, Uxbridge, UK.

Journal of medical economics

|January 5, 2026

Resumen

No abstract available in PubMed .

Palabras clave:

H2O y H3O I10 y No obstante, el No obstante, el KRAS G12C el adagrasibo rentabilidad Cáncer de pulmón de células no pequeñas el sotorasibo

Más Videos Relacionados

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

Videos de Conceptos Relacionados

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...